Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma

[1] Richardson PG(2009)Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline Br J Haematol 144 895-903

[2] Sonneveld P(2008)Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma Haematologica 93 1908-1911

[3] Schuster MW(2011)Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 431-440

[4] Stadtmauer EA(2011)Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events Anticancer Res 31 2297-2302

[5] Facon T(2010)Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma Blood 115 3416-3417

[6] Harousseau JL(2012)Cutaneous lesion induced by a subcutaneous administration of bortezomib Clin Lymphoma Myeloma Leuk 12 284-undefined

[7] Moreau P(2005)Skin lesions induced by bortezomib Haematologica 90 ECR44-undefined

[8] Coiteux V(undefined)undefined undefined undefined undefined-undefined

[9] Hulin C(undefined)undefined undefined undefined undefined-undefined

[10] Leleu X(undefined)undefined undefined undefined undefined-undefined

[1] Richardson PG(2009)Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline Br J Haematol 144 895-903

[2] Sonneveld P(2008)Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma Haematologica 93 1908-1911

[3] Schuster MW(2011)Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 431-440

[4] Stadtmauer EA(2011)Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events Anticancer Res 31 2297-2302

[5] Facon T(2010)Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma Blood 115 3416-3417

[6] Harousseau JL(2012)Cutaneous lesion induced by a subcutaneous administration of bortezomib Clin Lymphoma Myeloma Leuk 12 284-undefined

[7] Moreau P(2005)Skin lesions induced by bortezomib Haematologica 90 ECR44-undefined

[8] Coiteux V(undefined)undefined undefined undefined undefined-undefined

[9] Hulin C(undefined)undefined undefined undefined undefined-undefined

[10] Leleu X(undefined)undefined undefined undefined undefined-undefined